James L. Wade

14.7k total citations · 4 hit papers
153 papers, 7.6k citations indexed

About

James L. Wade is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, James L. Wade has authored 153 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in James L. Wade's work include Cancer Treatment and Pharmacology (27 papers), Lung Cancer Treatments and Mutations (25 papers) and Colorectal Cancer Treatments and Studies (19 papers). James L. Wade is often cited by papers focused on Cancer Treatment and Pharmacology (27 papers), Lung Cancer Treatments and Mutations (25 papers) and Colorectal Cancer Treatments and Studies (19 papers). James L. Wade collaborates with scholars based in United States, Canada and France. James L. Wade's co-authors include Thomas J. Smith, David Cella, George D. Demetri, Mark G. Kris, L Degos, Jamés O. Armitage, Jeffrey Crawford, Antoinette J. Wozniak, George Somlo and Charles L. Bennett and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

James L. Wade

148 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines

2000 629 citations James L. Wade, Antoinette J. Wozniak et al. Journal of Clinical Oncology profile →
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1998 606 citations James L. Wade et al. Journal of Clinical Oncology profile →
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

2015 589 citations Natasha B. Leighl, James L. Wade et al. Journal of Clinical Oncology profile →
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

2021 175 citations Davendra Sohal, Muhammad Shaalan Beg et al. profile →

Peers

Countries citing papers authored by James L. Wade

Since Specialization

Citations

This map shows the geographic impact of James L. Wade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Wade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Wade more than expected).

Fields of papers citing papers by James L. Wade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Wade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Wade. The network helps show where James L. Wade may publish in the future.

Co-authorship network of co-authors of James L. Wade

This figure shows the co-authorship network connecting the top 25 collaborators of James L. Wade. A scholar is included among the top collaborators of James L. Wade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Wade. James L. Wade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma 2024 ·Gastroenterology ·Max M. Wattenberg, (unknown), Ignacio Garrido‐Laguna, (unknown), (unknown), (unknown), Jesse Lee, Kajsa E. Affolter, Sean J. Mulvihill, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, Katherine A. Guthrie, E. Gabriela Chiorean, Syed A. Ahmad, Andrew M. Lowy, Philip Agop Philip, Davendra Sohal, Gregory L. Beatty	11
2	Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116) 2024 ·Journal of Clinical Oncology ·Stephen R. Rapp, Emily V. Dressler, W. Mark Brown, James L. Wade, Nguyet Le‐Lindqwister, David M. King, Kendrith M. Rowland, Kathryn E. Weaver, Heidi D. Klepin, Edward G. Shaw, Glenn J. Lesser	9
3	A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis 2024 ·Blood Advances ·Chenyu Lin, Anand Patel, Dezheng Huo, Theodore Karrison, Koen van Besien, John E. Godwin, Dorie Sher, (unknown), Margaret Green, James L. Wade, Rebecca B. Klisovic, Maria R. Baer, Richard A. Larson, Wendy Stock, Olatoyosi Odenike	1
4	A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study. 2024 ·Journal of Clinical Oncology ·Alexander T. Pearson, Tanguy Y. Seiwert, Roger B. Cohen, Nabil F. Saba, John M. Kaczmar, Mary J. Fidler, James L. Wade, Enrico Castellucci, Theodore Karrison, Rohan Katipally, Aditya Juloori, Ari J. Rosenberg, Daniel J. Haraf, Nishant Agrawal, Everett E. Vokes	4
5	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients 2021 ·JNCI Journal of the National Cancer Institute ·Veena Shankaran, Joseph M. Unger, Amy K. Darke, Jennifer M. Suga, James L. Wade, Peter J. Kourlas, Sreenivasa R Chandana, Mark Allen O’Rourke, (unknown), (unknown), Dawn L. Hershman, Scott D. Ramsey	39
6	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) 2021 ·Journal for ImmunoTherapy of Cancer ·Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William Irvin, Sreekanth Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Thomas E. Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara	38
7	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study 2020 ·Cancer ·Tanguy Y. Seiwert, Sara Kochanny, Kevin Wood, Francis P. Worden, Douglas R. Adkins, James L. Wade, Bethany Sleckman, Daniel M. Anderson, Ryan J. Brisson, Theodore Karrison, Walter M. Stadler, Everett E. Vokes	15
8	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) 2018 ·Breast Cancer Research and Treatment ·Sherry Shen, Joseph M. Unger, Katherine D. Crew, Cathee Till, Heather Greenlee, Julie R. Gralow, Shaker R. Dakhil, Lori M. Minasian, James L. Wade, Michael Fisch, N. Lynn Henry, Dawn L. Hershman	33
9	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer 2016 ·Investigational New Drugs ·Shivaani Kummar, James L. Wade, Amit M. Oza, Daniel M. Sullivan, Alice P. Chen, David R. Gandara, Jiuping Ji, Robert J. Kinders, Lihua Wang, Deborah Allen, Geraldine O’Sullivan Coyne, Seth M. Steinberg, James H. Doroshow	64
10	An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Pierre Maison‐Blanche, Shaker R. Dakhil, Ari David Baron, Sylvie Rottey, (unknown), Gedske Daugaard, Jean-Pascal Machiels, William R. Conkright, Sunil Sharma, Patricia M.M.B. Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter J. Van Veldhuizen, Sanjiv S. Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L. Wade	1
11	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy 2013 ·Journal of Clinical Oncology ·Dawn L. Hershman, Joseph M. Unger, Katherine D. Crew, Lori M. Minasian, Danielle Awad, Carol M. Moinpour, Lisa Hansen, Danika L. Lew, Heather Greenlee, Louis Fehrenbacher, James L. Wade, Siu‐Fun Wong, Gabriel N. Hortobágyi, Frank L. Meyskens, Kathy S. Albain	145
12	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer 2010 ·Cancer Prevention Research ·Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin, Reena S. Cecchini, James N. Atkins, Therese B. Bevers, Louis Fehrenbacher, Eduardo R. Pajon, James L. Wade, André Robidoux, Richard G. Margolese, Joan James, Carolyn D. Runowicz, Patricia A. Ganz, Steven E. Reís, Worta McCaskill‐Stevens, Leslie G. Ford, V. Craig Jordan, Norman Wolmark, (unknown)	438
13	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia 2010 ·Gynecologic Oncology ·Halla Nimeiri, Amit M. Oza, Robert J. Morgan, Dezheng Huo, Laurie Elit, James A. Knost, James L. Wade, Edem Agamah, Everett E. Vokes, Gini F. Fleming	71
14	Conducting oral examinations for cancer in general practice: what are the barriers? 2009 ·Family Practice ·James L. Wade, Helen Smith, Matthew Hankins, Carrie Llewellyn	47
15	A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma 2007 ·Cancer Biology & Therapy ·Edwin M. Posadas, Samir D. Undevia, (unknown), James L. Wade, Dimitrios Colevas, Theodore Karrison, Everett E. Vokes, Walter M. Stadler	18
16	Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial 2006 ·Obstetrical & Gynecological Survey ·Stephanie R. Land, D. Lawrence Wickerham, Joseph P. Costantino, (unknown), Victor G. Vogel, Myoungkeun Lee, Eduardo R. Pajon, James L. Wade, Shaker R. Dakhil, (unknown), Norman Wolmark, Patricia A. Ganz	58
17	Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program 2006 ·Lung Cancer ·Ramaswamy Govindan, Ronald B. Natale, James L. Wade, Roy S. Herbst, Annetta Krebs, (unknown), Thomas A. Hensing, Antoinette J. Wozniak, Chandra P. Belani, Karen Kelly, Judith Ochs	9
18	Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998) 2004 ·Leukemia ·Peter H. Wiernik, Elisabeth Paietta, Olga Goloubeva, (unknown), Della Makower, John M. Bennett, James L. Wade, C Ghosh, Lynne Kaminer, John G. Pizzolo, Martin S. Tallman, (unknown)	20
19	Mobile Surgical Transport Team 1998 ·AORN Journal ·(unknown), James L. Wade, (unknown), William B. Long	3
20	Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. 1993 ·Journal of Clinical Oncology ·Melody Cobleigh, Kambiz Dowlatshahi, (unknown), Rajendra G. Mehta, R C Moon, Fredrick L. Minn, Al B. Benson, Alfred Rademaker, (unknown), James L. Wade	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact